XON 9
Alternative Names: XON-9Latest Information Update: 03 Mar 2023
At a glance
- Originator Xenothera
- Class Antibodies; Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 01 Dec 2022 Preclinical trials in Haematological malignancies in France (unspecified route) (Xenothera pipeline, December 2022)
- 01 Dec 2022 Preclinical trials in Solid tumours in France (unspecified route) (Xenothera pipeline, December 2022)